Roka Bioscience, Inc., a molecular diagnostics company, focuses on the development and commercialization of molecular assay technologies for the detection of foodborne pathogens in the United States. It provides Atlas instrument, a fully automated molecular diagnostic testing instrument to reduce labor costs and operator error in high-volume foodborne pathogen testing laboratories. The company also offers atlas detection assays that include molecular tests for Salmonella, Listeria, E. coli O157:H7, Shiga toxin- producing E.coli, and Listeria monocytogenes, as well as related consumable supplies. It serves food processors, third-party contract testing laboratories, and government regulatory a...
20 Independence Boulevard
Warren, NJ 07059
Founded in 2009
Roka Bioscience, Inc. Reports Unaudited Earnings Results for the Third Quarter and Nine Months Ended September 30, 2015
Nov 11 15
Roka Bioscience, Inc. reported unaudited earnings results for the third quarter and nine months ended September 30, 2015. For the quarter, the company reported revenue of $1,508,000 against $1,483,000 a year ago. Loss from operations was $8,083,000 against $8,373,000 a year ago. Loss before income taxes was $8,487,000 against $9,072,000 a year ago. Net loss and comprehensive loss was $8,491,000 against $9,083,000 a year ago. Basic and diluted net loss per share was $0.49 against $0.64 a year ago. The increase in third quarter revenue year-on-year resulted from an increase in the number of Atlas(R) instruments placed with commercial customers and increased commercial utilization of the instruments.
For the nine months, the company reported revenue of $4,484,000 against $3,701,000 a year ago. Loss from operations was $24,994,000 against $22,742,000 a year ago. Loss before income taxes was $26,582,000 against $24,771,000 a year ago. Net loss and comprehensive loss was $26,592,000 against $24,799,000 a year ago. Basic and diluted net loss per share was $1.54 against $4.78 a year ago.
Roka Bioscience, Inc. Appoints Lars Boesgaard as Vice President and Chief Financial Officer to Replace Steven Sobieski
Nov 11 15
Roka Bioscience, Inc. announced the appointment of Lars Boesgaard as Vice President and Chief Financial Officer. Mr. Boesgaard, who joined Roka in 2009 and currently serves as Vice President, Finance and Controller, succeeds Steven Sobieski. Mr. Sobieski will continue his association with the company as a Senior Advisor. Mr. Boesgaard has 20 years of finance and accounting experience. He joined Roka in October 2009 as Controller and was promoted to Vice President, Finance in January 2012.
Roka Bioscience, Inc. to Report Q3, 2015 Results on Nov 11, 2015
Nov 4 15
Roka Bioscience, Inc. announced that they will report Q3, 2015 results at 5:00 PM, Eastern Standard Time on Nov 11, 2015